이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sartorius Stedim Biotech 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rene Faber

최고 경영자

€790.0k

총 보상

CEO 급여 비율	68.4%
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Rene Faber 의 보수는 Sartorius Stedim Biotech 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	€255m
Dec 31 2023	€790k	€540k	€310m
Sep 30 2023	n/a	n/a	€460m
Jun 30 2023	n/a	n/a	€635m
Mar 31 2023	n/a	n/a	€717m
Dec 31 2022	€578k	€288k	€876m
Sep 30 2022	n/a	n/a	€681m
Jun 30 2022	n/a	n/a	€625m
Mar 31 2022	n/a	n/a	€559m
Dec 31 2021	€901k	€396k	€414m
Sep 30 2021	n/a	n/a	€523m
Jun 30 2021	n/a	n/a	€469m
Mar 31 2021	n/a	n/a	€398m
Dec 31 2020	€742k	€396k	€336m
Sep 30 2020	n/a	n/a	€299m
Jun 30 2020	n/a	n/a	€255m
Mar 31 2020	n/a	n/a	€254m
Dec 31 2019	€784k	€425k	€235m

보상 대 시장: Rene 의 총 보상 ($USD 848.92K ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.73M ).

보상과 수익: Rene 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Rene Faber (49 yo)

1.3yrs

테뉴어

€790,000

보상

Dr. Rene Faber serves as Head of Bioprocess Solutions Division and Member of the Executive Board at Sartorius Aktiengesellschaft since January 01, 2019. He serves as Chief Executive Officer at Sartorius St...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rene Faber	CEO & DIrector	5.3yrs	€790.00k	데이터 없음
Joachim Kreuzburg	Non-Executive & Non-Independent Chairman	17yrs	€693.15k	0.000010% € 1.5k
Lothar Kappich	Director	6.8yrs	€84.00k	0% € 0
Henri Riey	Director	17yrs	€56.00k	0.000010% € 1.5k
Pascale Boissel	Independent Director	5.3yrs	€93.00k	0% € 0
Anne-Marie Graffin	Lead Independent Director	9.2yrs	€91.00k	0.000010% € 1.5k
Susan Dexter	Independent Director	9.2yrs	€84.00k	0.000010% € 1.5k
Romaine Fernandes	Employee Representative Non - Executive Director	less than a year	데이터 없음	0% € 0

8.0yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: DIMP 의 이사회는 경험(평균 재직 기간 8 년)으로 간주됩니다.

Sartorius Stedim Biotech 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Less than half of directors are independent

Recent updates

Insufficient new directors

Investor sentiment deteriorates as stock falls 27%

Insufficient new directors

Upcoming dividend of €0.69 per share

New minor risk - Profit margin trend

Dividend of €0.69 announced

Insufficient new directors

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 15%

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Less than half of directors are independent

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €362

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령